The finding from an 18-month-long clinical trial strengthens hope that pharmacotherapy can break nicotine’s especially tenacious hold on people with serious mental illness such as bipolar disorder or schizophrenia.
Presents a summary of a study that followed individuals who entered mental health crisis or substance abuse detoxification residential centers in San Francisco and the types of treatment they received.
People who use prescription opiates nonmedically are more likely to consider suicide than those who use these medications only appropriately or not at all. A recent NIDA-supported study also disclosed that the risk for suicidal thoughts remains elevated after cessation of use.
People with cannabis use disorder (CUD) are likely also to have social anxiety disorder (SAD), and comorbid SAD is associated with greater severity of cannabis-related problems. These findings highlight the importance of assessing CUD patients for SAD, as that disorder can be both a contributing cause and a consequence of CUD. Treating both disorders may be a key to helping patients recover from each.
Treatment with an extended-release stimulant medication plus cognitive behavioral therapy was associated with reductions in cocaine use and in attention-deficit/hyperactivity disorder symptoms in patients with both disorders.